Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Takeda kicks off sale of Western European drugs - sources

Published 2019-07-17, 12:55 p/m
Updated 2019-07-17, 01:00 p/m
© Reuters.  Takeda kicks off sale of Western European drugs - sources

© Reuters. Takeda kicks off sale of Western European drugs - sources

By Arno Schuetze and Pamela Barbaglia

FRANKFURT/LONDON, July 17 (Reuters) - Japan's Takeda Pharmaceutical Co 4502.T has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters.

Takeda is hoping to fetch around 1.5 billion euros ($1.68 billion) from the sale and has sent out information packages to interested parties, the sources said.

The drugs on the block include over-the-counter (OTC) and prescription medicines, patents for most of which have run out, meaning they can be copied by generic drug makers.

The assets have combined earnings before interest, tax, depreciation and amortization (EBITDA) of about 160 million euros, the sources said, with OTC drugs accounting for about 40 million euros.

Takeda is working with JPMorgan (NYSE:JPM) to find a new owner and wants to receive indicative bids after the summer, the sources said.

Takeda and JPMorgan declined to comment.

The sale comes amid a wave of multi-billion dollar deals as drugmakers seek to buy other companies to combat expiring patents on their blockbuster medicines and renew their drug pipelines.

While the acquisition of Shire gave Takeda global heft, it also left it highly indebted, with 5.7 trillion yen ($52.73 billion) of debt as of end-March this year.

Japan's biggest drugmaker said in January it would dispose of $10 billion worth of assets. It subsequently sold its dry-eye drug Xiidra to Novartis NOVN.S for up to $5.3 billion. group has pledged to focus on five key areas - oncology, gastroenterology, neuroscience, rare disease, and plasma-derived therapies – which contribute about 75% of its total revenue, while disposing of the rest.

It is hoping to clinch a deal for its Western European drugs with either an industry player or a private equity firm, the sources said, adding the portfolio could also be split and offered to two sets of bidders.

The OTC drugs are expected to draw interest from the likes of Germany's Stada STAGn.D , France's Zentiva and Italy's Recordati RECI.MI , the sources said.

The remainder of the business may appeal to industry players who are seeking to expand their distribution channels and increase penetration of their own drugs, they added.

Another source said while there is no obvious buyer for the entire portfolio, private equity funds with existing healthcare investments - such as Cinven and Bain Capital, who jointly back Stada, and Asian players, particularly Indian pharmaceutical companies - are likely get involved as they want scale in Europe.

Takeda is also in the process of divesting its Latin American assets, which are valued at about $1 billion.

The Latam sale is in the final stages, with Brazilian pharmaceutical firm EMS seen as the frontrunner, the sources said. Benckiser RB.L and Uruguay's Megalabs have been shortlisted along with EMS to submit binding offers for the Latam portfolio, but are less likely to win, they said.

EMS, Reckitt and Megalabs declined to comment. ($1 = 0.8908 euros) ($1 = 108.1000 yen)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.